#USA #Carlsbad #Hepatitis B #Pictor Holdings #ViraScreen-Core

Pictor's Groundbreaking Assay for Hepatitis B Immunity Testing

As suggestions from the CDC's Advisory Committee on Immunization Practices (ACIP) begin to reshape standard practices in health testing, Pictor Holdings Inc. steps forward with an impressive solution. Their ViraScreen-Core™ multiplex antibody assay is poised to make a significant impact on the hepatitis B immunity testing landscape.

The Shifting Landscape of Hepatitis B Testing

Hepatitis B has long been recognized as a significant global health threat, yet testing methods have often struggled with affordability and operational difficulties. The recent shift in CDC guidelines that advocate for post-vaccination antibody testing emphasizes the need for labs to more accurately assess immunity. Pictor, with its expertise in targeted proteomics, is addressing these challenges through innovative technology.

The ViraScreen-Core™ assay is already being utilized in CLIA-certified laboratories. This advanced test is adaptable for both serum and saliva samples, providing laboratories with the flexibility required to meet new public health guidelines without compromising operational efficiency.

Advantages of the ViraScreen-Core™ Assay

The beauty of the ViraScreen-Core™ assay lies in its multiplex capability, which facilitates the simultaneous detection of antibodies for hepatitis B, HIV-1, HIV-2, and hepatitis C from a single sample. This revolutionary method not only enhances the accuracy of testing but also reduces turnaround times and conserves patient samples. In a healthcare environment where timely and reliable results are crucial, this assay enables informed, evidence-based clinical decision-making.

Dr. Jamie Platt, CEO of Pictor, shares insights into the assay’s significance: "Antibody testing gives laboratories flexibility as public health guidance evolves. By offering a multiplex assay that works with both serum and saliva, we aim to help labs move toward evidence-based immunity assessment without adding operational complexity."

Validation and Reliability of Saliva Testing

Pictor has undertaken studies to validate the use of saliva as a testing medium, demonstrating high concordance with traditional serum testing. This breakthrough could substantially lower barriers to testing, especially in settings like pediatrics or community health where blood draws can be challenging. The prospect of saliva-based testing is a significant step toward making healthcare more accessible.

Dr. Andrew Brown, Chief Commercial Officer at Sirona Dx, remarks on the assay's value, noting that, "Compatibility with saliva samples expands the environments in which testing can be conducted while the multiplex format supports streamlined, efficient workflows for infectious disease screening." This versatility can bolster public health initiatives aimed at increasing screening rates and improving diagnosis.

Looking Toward the Future

Pictor's commitment to innovation is reflected in its ongoing efforts to secure capital for further commercialization of their technologies and the expansion of their assay menu. As they move forward, the company aims to enhance accessibility to their targeted proteomics platform across the United States, utilizing its technology that has already seen early adoption in laboratories.

For healthcare providers and laboratories, the ViraScreen-Core™ assay represents a significant advancement in hepatitis B immunity testing. By blending cutting-edge technology with a commitment to improving public health, Pictor Holdings Inc. is not just shaping the future of proteomics testing but also playing a crucial role in global health management.

To learn more about Pictor's ViraScreen-Core™ assay and its impact on hepatitis B testing, visit Pictor's website.

About Pictor Holdings Inc.

Pictor specializes in advanced multiplex solutions that enhance diagnostic capabilities worldwide. With its patented PictArray™ and other innovative technologies, Pictor is positioned at the forefront of the proteomics field, contributing to faster, more accurate healthcare solutions. For more details on their advancements, visit Pictor's website.

For media inquiries, contact Kelly Krueger at 415-235-5031 or email [email protected].